Products Detail
SumiLarv® 2MR is a polymer matrix release formulation presented as a 5.5 cm diameter plastic disc weighing 2 g containing 2% w/w pyriproxyfen. SumiLarv® 2MR should be placed in water containers at a rate of one disc per 40-500 litres of water, depending on local registration. The disc will sink to the bottom of the container, with pyriproxyfen releasing slowly from the matrix to give a long duration of efficacy. When cleaning containers place the disc in the shade and put back into the container after refilling with water.
Key Features
SumiLarv® (pyriproxyfen): Mode of Action
SumiLarv® 2MR is a novel mosquito larval control product for use against container breeding mosquitoes, based on the insect growth regulator (IGR) pyriproxyfen. Pyriproxyfen was invented and developed by Sumitomo Chemical Co., Ltd. and has a unique mode of action that is insect-specific, stage-specific, and not neurotoxic.
Pyriproxyfen does not directly kill mosquito larvae, but strongly prevents adult emergence. The late 4th larval stage and pupae just after pupation are the most susceptible to pyriproxyfen (Y.Kono et al., Medical Entomology & Zoology, 48(2), 85-89, 1997).
Since larvae do not die immediately after treatment, users need to adjust to the concept that although larvae can still be seen following an application of SumiLarv® 2MR, mortality will normally occur at the pupal/ adult moult thus preventing the emergence of adult mosquitoes. For this reason, evaluation of pyriproxyfen is determined by measuring adult emergence inhibition.
Application of SumiLarv® 2MR to the aquatic larval habitat reduces the emergence of adult mosquitoes which in turn reduces biting rates. Pyriproxyfen has received U.S. EPA status as a reduced risk insecticide and an organophosphate alternative and is recognized by the WHO for treatment of potable water against mosquitoes (Sullivan, J.J. & Goh, K.S., Journal Pesticide Science, 33(4) 339-350, 2008).
Target Pests
Mosquito
Key Features
- Easy to use
- Effective for over 6 months – an operational cost saving compared to conventional larvicides
- Slow release technology
- No odour
- Discs are easy to see – helping to identify and track treatments
SumiLarv® (pyriproxyfen): Mode of Action
SumiLarv® 2MR is a novel mosquito larval control product for use against container breeding mosquitoes, based on the insect growth regulator (IGR) pyriproxyfen. Pyriproxyfen was invented and developed by Sumitomo Chemical Co., Ltd. and has a unique mode of action that is insect-specific, stage-specific, and not neurotoxic.
Pyriproxyfen does not directly kill mosquito larvae, but strongly prevents adult emergence. The late 4th larval stage and pupae just after pupation are the most susceptible to pyriproxyfen (Y.Kono et al., Medical Entomology & Zoology, 48(2), 85-89, 1997).
Since larvae do not die immediately after treatment, users need to adjust to the concept that although larvae can still be seen following an application of SumiLarv® 2MR, mortality will normally occur at the pupal/ adult moult thus preventing the emergence of adult mosquitoes. For this reason, evaluation of pyriproxyfen is determined by measuring adult emergence inhibition.
Application of SumiLarv® 2MR to the aquatic larval habitat reduces the emergence of adult mosquitoes which in turn reduces biting rates. Pyriproxyfen has received U.S. EPA status as a reduced risk insecticide and an organophosphate alternative and is recognized by the WHO for treatment of potable water against mosquitoes (Sullivan, J.J. & Goh, K.S., Journal Pesticide Science, 33(4) 339-350, 2008).
Target Pests
Mosquito